Marksans Pharma Limited has informed the Exchange about Transcript
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma reported Q1 FY26 revenue of ₹620 crore, up 5% YoY, but profit after tax fell 34.7% to ₹58.2 crore due to a 560 bps drop in EBITDA margin (to 16.1%) from one-off items like ₹10.48 crore ECL provision, ₹6.2 crore forex MTM loss, and higher employee costs from new facility hiring. US/North America revenue grew strongly 30.6% YoY to ₹327.6 crore, while UK business saw sharp price erosion (~20% YoY decline) on its 40% Rx portfolio due to cascading tariff-related global demand shifts. Gross margin expanded 209 bps to 57.8% on lower input costs. The company disclosed a US order book of $220 million (with $45-50M execution starting Oct-Dec) and remains debt-free with ₹711 crore cash. New Goa facility is near-ready and Teva facility utilization is ramping toward ₹500 crore (target ₹800 crore).
Near-term sentiment is likely weak given the sharp PAT decline and UK pricing pressure, but management's guidance for sequential margin improvement and a strong US order pipeline provides comfort on the medium-term growth path. Revenue may fall short of the earlier ₹3,000 crore FY26 target, with year-on-year EBITDA margins likely flat rather than expanding.